Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC).

被引：1
|
作者：
Sonpavde, Guru
Bhor, Menaka
Hennessy, Daniel
Bhowmik, Debajyoti
Shen, Liji
Schnadig, Ian D.
机构：
[1] UAB Comprehens Canc Ctr, Birmingham, AL USA
[2] McKesson Specialty Hlth, The Woodlands, TX USA
[3] US Oncol Network, The Woodlands, TX USA
[4] Sanofi Aventis, Bridgewater, NJ USA
[5] Compass Oncol, Portland, OR USA
[6] US Oncol Network, Portland, OR USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.223
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
223
引用
收藏
页数：1
相关论文
共 50 条
  • [11] BURDEN OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN TURKEY
    Erdal, E.
    Malhan, S.
    Oksuz, E.
    Benekli, M.
    Cag, C.
    Dane, F.
    Kabasakal, L.
    Kucuk, O.
    Sozen, T. S.
    Sar, C.
    Kahveci, B.
    VALUE IN HEALTH, 2016, 19 (07) : A725 - A726
  • [12] Testosterone levels in metastatic castration-resistant prostate cancer (mCRPC).
    von Klot, Christoph A. J.
    Boeker, Alena
    Herrmann, Thomas R. W.
    Kramer, Mario W.
    Kuczyk, Markus A.
    Merseburger, Axel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [13] A phase II study of sunitinib (SU) for maintenance therapy in metastatic castration-resistant prostate cancer (mCRPC) after response to docetaxel (D)
    Eigl, B. J.
    Trudeau, M. G.
    Winquist, E.
    Chi, K. N.
    Eliasziw, M.
    North, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [14] Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Adesunloye, Bamidele
    Huang, Xuan
    Ning, Yangmin M.
    Madan, Ravi A.
    Gulley, James L.
    Beatson, Melony
    Kluetz, Paul Gustav
    Adelberg, David E.
    Arlen, Philip M.
    Parnes, Howard L.
    Mulquin, Marcia
    Steinberg, Seth M.
    Wright, John Joseph
    Trepel, Jane B.
    Dawson, Nancy Ann
    Chen, Clara
    Bassim, Carol
    Apolo, Andrea Borghese
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [15] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sebastian Christoph Schmid
    Alexander Geith
    Alena Böker
    Robert Tauber
    Anna Katharina Seitz
    Markus Kuczyk
    Christoph von Klot
    Jürgen Erich Gschwend
    Axel Stuart Merseburger
    Margitta Retz
    Advances in Therapy, 2014, 31 : 234 - 241
  • [16] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Schmid, Sebastian Christoph
    Geith, Alexander
    Boeker, Alena
    Tauber, Robert
    Seitz, Anna Katharina
    Kuczyk, Markus
    von Klot, Christoph
    Gschwend, Juergen Erich
    Merseburger, Axel Stuart
    Retz, Margitta
    ADVANCES IN THERAPY, 2014, 31 (02) : 234 - 241
  • [17] Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer
    Shen, Yuan-Chi
    Chiang, Po-Hui
    Luo, Hao-Lun
    Chuang, Yao-Chi
    Chen, Yen-Ta
    Kang, Chih-Hsiung
    Hsu, Chun-Chien
    Lee, Wei-Ching
    Cheng, Yuan-Tso
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2016, 32 (09): : 458 - 463
  • [18] Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC)
    Charles J. Ryan
    Sandipan Dutta
    William K. Kelly
    Carly Russell
    Eric J. Small
    Michael J. Morris
    Mary-Ellen Taplin
    Susan Halabi
    Prostate Cancer and Prostatic Diseases, 2020, 23 : 66 - 73
  • [19] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [20] Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)
    Parimi, Sunil
    Eliasziw, Misha
    North, Scott
    Trudeau, Marc
    Winquist, Eric
    Chi, Kim N.
    Ruether, Dean
    Cheng, Tina
    Eigl, Bernhard J.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (06) : 771 - 776
12345